20 September 2018 - - US-based cancer immunotherapy company Immune-Onc Therapeutics, Inc has appointed Dr. Adrian Jubb as chief medical officer and of Dr. An Song as senior vice president of development sciences, the company said.

Jubb joins Immune-Onc from Achaogen where he served as vice president and head of early development.

Song joins Immune-Onc from Genentech where she held positions of increasing responsibility over her 16-year tenure at the company and most recently served as a senior director within Genentech's Research and Early Development organisation.

In addition, Immune-Onc announced it received series B funding of more than USD 33m from leading investors, including Northern Light Venture Capital, Vivo Capital, and the Stanford-StartX Fund, to advance its pipeline programmes.

As chief medical officer, Jubb is accountable for the clinical and regulatory strategy and execution of Immune-Onc's portfolio.

As senior vice president of development sciences, Song has overall accountability for translational development of Immune-Onc's portfolio, including preclinical PKPD and toxicology evaluation, clinical pharmacology, bioanalytical and biomarker/diagnostic development and certain analytical aspects of technical development.

Both Jubb and Song are based at Immune-Onc's headquarters in Palo Alto and will join the company's executive committee.

Immune-Onc Therapeutics, Inc. is a privately held cancer immunotherapy company dedicated to the discovery and development of novel biologic treatments for cancer patients.

The company aims to translate unique scientific insights in the tumor microenvironment and immune suppressive pathways to develop first-in-class biotherapeutics.

Immune-Onc has a promising pipeline built upon strategic collaborations and cutting-edge research from The University of Texas, Albert Einstein College of Medicine, and Memorial Sloan Kettering Cancer Center.

Headquartered in Palo Alto, California, Immune-Onc has assembled a diverse team with deep expertise in drug development and proven track records of success at leading biotechnology companies.